CRVS•Phase 1 atopic dermatitis results showed 75% of participants achieved EASI75, with no serious adverse events; Corvus expects SIERRA1 Phase 2 topline data in the third quarter of 2027.
Corvus Pharmaceuticals said Phase 1 atopic dermatitis results showed 75% achieved EASI75, with no serious adverse events. The company expects SIERRA1 Phase 2 atopic dermatitis topline data in the third quarter of 2027; a PTCL Phase 3 interim futility analysis is due in the first quarter of 2027, with topline data expected at year-end. Initial hidradenitis suppurativa Phase 1b data are expected in the first half of 2027, and cash runway extends into the second quarter of 2028.
